Table 1. Characteristics of patient with thyroid-associated ophthalmopathy from whom orbital fibroblasts were obtained.

TAO Patient number	Age	Sex	Smoking	Grave’s disease	Grave’s disease treatment			TAO treatment			Euthyroid state	TSH receptor antibody	CAS
					Radioactive Iodine	Methimazole	Thyroidectomy	Surgery	Prednisolone	Radiation
#103	23	F	No	Yes	No	Yes	No	Yes	No	No	Yes	+	2
#107	50	F	No	Yes	No	Yes	No	Yes	Yes	Yes	Yes	+	3
#110	65	M	No	Yes	No	No	Yes	Yes	Yes	No	Yes	+	1
#120	56	M	Yes	Yes	No	Yes	No	Yes	Yes	No	Yes	+	3
#135	61	M	No	Yes	No	Yes	No	Yes	Yes	No	Yes	+	1
#137	59	F	No	Yes	No	Yes	No	Yes	Yes	No	Yes	+	3
#162	73	F	No	Yes	No	Yes	No	Yes	Yes	No	Yes	+	3

All patients with TAO had experienced at least 6 months of inactive disease status with a euthyroid hormonal condition.

Non-TAO patients; #71 (female, 61 years), #111 (female, 68 years), #116 (male, 60 years), #136 (male, 59 years), #150 (female, 65 years), #152 (female, 22 years), #155 (male, 70 years), #158 (male, 75 years).

CAS, clinical activity score; TSH, thyroid-stimulating hormone.